Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 3
2017 1
2018 3
2019 2
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Photosensitizers Based on G-Quadruplex Ligand for Cancer Photodynamic Therapy.
Kawauchi K, Urano R, Kinoshita N, Kuwamoto S, Torii T, Hashimoto Y, Taniguchi S, Tsuruta M, Miyoshi D. Kawauchi K, et al. Among authors: taniguchi s. Genes (Basel). 2020 Nov 12;11(11):1340. doi: 10.3390/genes11111340. Genes (Basel). 2020. PMID: 33198362 Free PMC article. Review.
[Insulin resistance].
Ura N, Taniguchi S. Ura N, et al. Among authors: taniguchi s. Nihon Rinsho. 2006 Jul;64 Suppl 5:259-64. Nihon Rinsho. 2006. PMID: 16895193 Review. Japanese. No abstract available.
Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
Nakajima A, Seki M, Taniguchi S. Nakajima A, et al. Among authors: taniguchi s. J Gastroenterol. 2018 Apr;53(4):525-534. doi: 10.1007/s00535-017-1383-5. Epub 2017 Aug 24. J Gastroenterol. 2018. PMID: 28840422 Free PMC article. Clinical Trial.
Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A, Seki M, Taniguchi S, Ohta A, Gillberg PG, Mattsson JP, Camilleri M. Nakajima A, et al. Among authors: taniguchi s. Lancet Gastroenterol Hepatol. 2018 Aug;3(8):537-547. doi: 10.1016/S2468-1253(18)30123-7. Epub 2018 May 25. Lancet Gastroenterol Hepatol. 2018. PMID: 29805116 Clinical Trial.
13 results